Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.
Mejia
Andres F
AF
Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033-2390, USA.
Culp
Timothy D
TD
Cladel
Nancy M
NM
Balogh
Karla K
KK
Budgeon
Lynn R
LR
Buck
Christopher B
CB
Christensen
Neil D
ND
D000818:Animals; D036022:Capsid Proteins / Q000276:immunology*; D012777:Cottontail rabbit papillomavirus / Q000276:immunology*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D052140:Human papillomavirus 11 / Q000276:immunology*; D052162:Human papillomavirus 16 / Q000276:immunology*; D030361:Papillomavirus Infections / Q000473:pathology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014771:Virion / Q000276:immunology*
D036022:Capsid Proteins; D053918:Papillomavirus Vaccines; D011993:Recombinant Fusion Proteins